Topics

CStone Acquires China Rights to Tri-Specific Cancer Immunotherapy from Numab

23:52 EDT 2 May 2019 | ChinaBio Today

Suzhou's CStone Pharma acquired Greater China rights to a tri-specific PD-L1 antibody developed by Zurich's Numab in exchange for funding R&D of the molecule through a Phase I clinical trial. ND021 is a late-preclinical molecule that targets PD-L1, 4-1BB, and human serum albumin (HSA). Because it activates T cells only when binding PD-L1 on tumor cells, ND021 is expected to avoid the liver toxicities of other 4-1BB-agonistic antibodies. CStone notes that once the Phase Ib trial is completed, it will have no other financial obligations for ND021. More details....

Stock Symbol: (HK: 2616)

Share this with colleagues:

Original Article: CStone Acquires China Rights to Tri-Specific Cancer Immunotherapy from Numab

NEXT ARTICLE

More From BioPortfolio on "CStone Acquires China Rights to Tri-Specific Cancer Immunotherapy from Numab"

Quick Search

Relevant Topics

Antibodies
An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...